Read by QxMD icon Read


Pegah Hashemi, Hasan Bagheri, Abbas Afkhami, Salimeh Amidi, Tayyebeh Madrakian
A novel electrochemical sensor for sensitive determination of ampyra (Am) based on graphene nanoribbons modified by iron-platinum bimetallic nanoparticles and uric acid (SPCE/FePtGNR/UA) dropped on the screen-printed carbon electrode (SPCE) surface and magnetically captured onto an SPCE working electrode surface is reported in the present work. The modified nanocomposite and sensing layer was characterized by different techniques, including cyclic voltammetry (CV), linear sweep voltammetry (LSV), electrochemical impedance spectroscopy (EIS), transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FT-IR) and X-ray powdered diffraction (XRD)...
January 1, 2018: Talanta
Pegah Hashemi, Abbas Afkhami, Hasan Bagheri, Salimeh Amidi, Tayyebeh Madrakian
This paper presents a novel impedimetric sensor for the sensitive determination of ampyra (Am) based on the l-Cysteine/Cu (II) modified gold electrode (Cu (II)/L-Cys/AuE). This novel sensing layer was characterized by different techniques, including atomic force microscopy (AFM), cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). Am determination by conventional electrochemical methods is not possible, because of its high redox overpotential. Therefore, [Fe(CN)6](3-/4-) was used as a redox probe for the impedimetric determination of Am...
September 1, 2017: Analytica Chimica Acta
Andrew R Blight, Herbert R Henney, Ron Cohen
Walking impairment is a clinical hallmark of multiple sclerosis (MS). Dalfampridine-ER, an extended-release formulation of dalfampridine (also known by its chemical name, 4-aminopyridine, and its international nonproprietary name, fampridine), was developed to maintain drug plasma levels within a narrow therapeutic window, and assessed for its ability to improve walking in MS. The putative mechanism of action of dalfampridine-ER is restoration of axonal conduction via blockade of the potassium channels that become exposed during axonal demyelination...
November 2014: Annals of the New York Academy of Sciences
Patrick P Gleason, Jill Phillips, Beckie A Fenrick, Ana Delgado-Riley, Catherine I Starner
BACKGROUND: Dalfampridine (Ampyra) is indicated to improve walking in patients with multiple sclerosis (MS) and was found to be effective in 35%-43% of individuals with MS in clinical trials. Dalfampridine may increase seizure risk, particularly in patients with renal impairment. A U.S. managed care expert consensus panel agreed that patient access to dalfampridine is best managed by a prior authorization (PA) in accordance with the FDA-approved labeling. To ensure safe and appropriate dalfampridine use, a health plan developed and implemented a 2-phase point-of-sale PA program...
January 2013: Journal of Managed Care Pharmacy: JMCP
Scott Weir, Risa Torkin, Herbert R Henney
BACKGROUND: In January 2010, dalfampridine extended release tablets (dalfampridine-ER [Ampyra *]; prolonged-, modified- or sustained-release fampridine [Fampyra †] in some countries), 10 mg to be administered twice daily approximately 12 hours apart, were approved by the US Food and Drug Administration. This was the first drug indicated to improve walking in patients with MS. SCOPE: Publications describing the pharmacokinetics of dalfampridine-ER or the immediate release formulation were identified from a search of PubMed through June 2012 using the search terms 'dalfampridine OR fampridine OR 4-aminopyridine' AND 'pharmacokinetics' and were supplemented with unpublished studies made available by Acorda Therapeutics Inc...
December 2013: Current Medical Research and Opinion
Scott Weir, Yuying Gao, Herbert R Henney
OBJECTIVE: Using data pooled from several studies of dalfampridine extended release (ER), a population pharmacokinetic model was developed for the purposes of characterizing the population pharmacokinetics and pharmacodynamics of dalfampridine-ER with respect to variability in pharmacokinetics, covariates affecting the pharmacokinetics, and whether the current therapeutic dosage represents an optimal dosage. Studies were conducted in healthy volunteers and multiple sclerosis (MS) patients over the course of development and registration of dalfampridine extended release tablets (dalfampridine-ER [Ampyra *]; prolonged-, modified- or sustained-release fampridine [Fampyra †] in some countries)...
December 2013: Current Medical Research and Opinion
Theodore E Pikoulas, Matthew A Fuller
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of dalfampridine. DATA SOURCES: A search of PubMed (1966-March 2012) was conducted using the words dalfampridine and Ampyra. Bibliographies of retrieved articles were reviewed to identify additional references. STUDY SELECTION AND DATA EXTRACTION: All identified studies published in English involving the efficacy and safety of dalfampridine were reviewed. DATA SYNTHESIS: Dalfampridine (Ampyra) is a broad-spectrum potassium channel blocker that is indicated as a treatment to improve walking in patients with multiple sclerosis (MS)...
July 2012: Annals of Pharmacotherapy
Peter I Jukkola, Amy E Lovett-Racke, Scott S Zamvil, Chen Gu
Voltage-gated K(+) (Kv) channels play critical roles not only in regulating synaptic transmission and intrinsic excitability of neurons, but also in controlling the function and proliferation of other cells in the central nervous system (CNS). The non-specific Kv channel blocker, 4-AminoPyridine (4-AP) (Dalfampridine, Ampyra®), is currently used to treat multiple sclerosis (MS), an inflammatory demyelinating disease. However, little is known how various types of Kv channels are altered in any inflammatory demyelinating diseases...
August 2012: Neurobiology of Disease
Jennifer M Belavic
No abstract text is available yet for this article.
November 2010: Nurse Practitioner
(no author information available yet)
No abstract text is available yet for this article.
September 20, 2010: Medical Letter on Drugs and Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"